Literature DB >> 10916143

Antibody humanization: a case of the 'Emperor's new clothes'?

M Clark1.   

Abstract

The antiglobulin response is perceived as a major problem in the clinical development of therapeutic antibodies. Successive technical developments such as chimeric, humanized and, now, fully human antibodies claim to offer improved solutions to this problem. Although there is clear evidence that chimeric antibodies are less immunogenic than murine monoclonal antibodies, little evidence exists to support claims for further improvements as a result of more elaborate humanization protocols.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10916143     DOI: 10.1016/s0167-5699(00)01680-7

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  48 in total

Review 1.  Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

Authors:  Nicole Selenko; Otto Majdic; Ulrich Jäger; Christian Sillaber; Johannes Stöckl; Walter Knapp
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317

Review 2.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

3.  Comparison of humanized IgG and FvFc anti-CD3 monoclonal antibodies expressed in CHO cells.

Authors:  Flavia Serpieri; Andre Inocencio; Jose Marcelino de Oliveira; Alécio A Pimenta; Angélica Garbuio; Jorge Kalil; Marcelo M Brigido; Ana Maria Moro
Journal:  Mol Biotechnol       Date:  2010-07       Impact factor: 2.695

4.  Antibody humanization by structure-based computational protein design.

Authors:  Yoonjoo Choi; Casey Hua; Charles L Sentman; Margaret E Ackerman; Chris Bailey-Kellogg
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

5.  Understanding differences between synthetic and natural antibodies can help improve antibody engineering.

Authors:  Anat Burkovitz; Yanay Ofran
Journal:  MAbs       Date:  2015-12-14       Impact factor: 5.857

6.  Trap for MAbs: characterization of intact monoclonal antibodies using reversed-phase HPLC on-line with ion-trap mass spectrometry.

Authors:  John C Le; Pavel V Bondarenko
Journal:  J Am Soc Mass Spectrom       Date:  2005-03       Impact factor: 3.109

7.  Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines.

Authors:  D Zagury; A Burny; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 8.  One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.

Authors:  Hyunbo Shim
Journal:  Exp Mol Med       Date:  2011-10-31       Impact factor: 8.718

9.  Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions.

Authors:  Sandeep Kumar; Satish K Singh; Xiaoling Wang; Bonita Rup; Davinder Gill
Journal:  Pharm Res       Date:  2011-03-25       Impact factor: 4.200

Review 10.  Antibody engineering to develop new antirheumatic therapies.

Authors:  John D Isaacs
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.